About us

Investors

Since our creation in December 2014, Seventure, a subsidiary of Natixis, with it’s the first European fund devoted to Microbiome investments “Health for Life”, has been a shareholder along with CM-CIC Innovation, one of the leading financers in high tech companies in France, Biocodex, an independent multinational pharmaceutical leader focused initially on probiotics, and finally the National Institute for Agricultural Research (INRA,) one of the leading academic centers in the field of Microbiota. As of March 2018, MaaT Pharma has raised 12 m€ in equity and 5+ m€ in non-dilutive funding thanks to the support from Bpifrance and our banking pool CIC and BNP Paribas .

About Seventure Partners

With over €691m in assets under management as of the end of 2017, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, especially fintech & assurtech, in France and Germany, and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include Biotechnology and Pharmaceuticals, Connected health and Medtech, Industrial biotechnology, and last but not least:  MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range from €500k to €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more information, please visit: www.seventure.com

About CM-CIC

CM-CIC Innovation is a subsidiary of CM-CIC Investissement, the Crédit Mutuel – CIC group’s investment and merchant bank division. With more than 2.6 billion Euros worth of equity under management and over 600 portfolio companies, CM-CIC Investissement is a key player in capital investment in France, backed by its own equity resources.

CM-CIC Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, information technology, industrial innovations or environment.

For more information,  please visit: http://www.cmcic-­investissement.com

About Biocodex

Biocodex is an independent family-owned pharmaceutical company, founded in Paris, France in 1953. The company initially concentrated on gastroenterology and specifically on the discovery of a promising probiotic substance, Saccharomyces boulardii (sold under the ULTRA-LEVURE brand in France). Biocodex has maintained partnerships with health sector professionals for 60 years, with the mission of developing intelligent solutions that respond to contemporary healthcare issues. Biocodex has become a multinational research and development, manufacturing and marketing company. The company is currently active in over 100 countries, with subsidiaries in Belgium, Russia, Ukraine, Turkey, Morocco, Mexico, the United States and through partnerships with distributors. Today, Biocodex specialises at international level in the therapeutic domains of gastroenterology, neuropsychiatry and pain treatment.

For more information, please visit:  www.biocodex.fr/en/

About INRA Transfert

The INRA Transfert portfolio includes 420 active licenses of patents, know-how and software exploitation generating annual royalty  turnover of over €4m. INRA Transfert manages 30 major European programs coordinated by INRA. INRA Transfert, the INRA subsidiary, is a company focused on project engineering and management of technology transfer to foster food, agricultural and environmental innovation. INRA Transfert enhances and manages the INRA technology portfolio through operating agreements with manufacturers and supports the development of innovative young companies.

As an intermediary between research and the business world, INRA Transfert has five main missions:

  • Transferring research results to companies by promoting and managing INRA’s portfolio of technologies, through operating agreements with the industrial sector.
  • Promoting the creation of innovative companies, by supporting their development
  • Supporting the setup, negotiation and management of European or national collaborative research projects by means of our expertise in project engineering.
  • Setting up and managing large partnership research programs
  • Providing resources to support innovation.

For more information,  please visit: http://www.inra-transfert.fr/en/

TEAM

Hervé Affagard

Hervé Affagard

Chief Executive Officer

Engineer, Executive MBA, Certificate “Exploring your Microbiome”

Hervé has lead the MaaT Pharma project since its inception in December 2014. Hervé previously worked as an entrepreneur in residence for venture capital firms relating to their investments in the healthcare field. In parallel, he also worked as a consultant for biotechnology companies where he led the transformation program. He was previously an executive director leading a multidisciplinary team at Biomnis, a specialist in medical testing. Combined with his previous experience at Bio-Rad, a top-10 medical diagnostics company, he brings to MaaT Pharma a strong track record in operational leadership in the life sciences field and a capacity to translate medical notions into a strategic business plan. Hervé was awarded Entrepreneur of the Year in Healthcare (2016) in recognition of his outstanding contribution to the development of Maat Pharma.

Siân Crouzet

Siân Crouzet

COO

CPA, IFRS Certified

Siân has lead the Finance and Operational functions at MaaT Pharma since 2016. Over the past 20 years, Siân has held various finance roles in international and multi-national environments, including 7 years as Principal Financial Officer and Director at Avadel Pharmaceuticals (AVDL), a Nasdaq-listed specialty pharma company. A member  of the senior management team, she was involved in raising capital of $130 million and has developed a wealth of experience in the financing, structuring and transformation of early-stage pharma businesses into commercially viable enterprises, including raising capital, M&A and business development. She began her career as a financial auditor with EY.

Corentin Le Camus

Corentin Le Camus

Therapeutic Development Director

PhD

Corentin Le Camus has led the Clinical operations since 2015. He holds a PhD in pharmaco-chemistry, pharmacology and metabolism from the University of Paris V. He is also an Executive MBA graduate from EM Lyon. Corentin has an international, multi-area experience in clinical development, including more than 10 years of experience in clinical project management within big pharma companies, such as Servier and Sanofi. Corentin has managed clinical trials from phase II to phase IV and projects of up to 18,000 patients. He also built up the clinical team at Olympus Biotech from inception of the company.

Carole Schwintner

Carole Schwintner

Pharmaceutical Development Director

PhD

Carole leads the Pharmaceutical Development and Product Development activities. After her PhD in molecular microbiology, she worked  as a post-doctoral fellow in yeast genetics. She then turned to industry as a translational/industrialization and analytical developments manager for biotechnology processes. She has held diverse responsibilities in manufacturing for a top 10 medical diagnostics company operating under GMP, including supply, scheduling, quality control, quality and manufacturing as Microbiology Production Director and a member of the site Steering Committee. In 2013, she moved to a start-up specialized in glycosylated proteins as COO, before joining MaaT Pharma in 2015.

Main Co-Founders

Hervé Affagard

Hervé Affagard

Chief Executive Officer

Engineer, Executive MBA, Certificate “Exploring your Microbiome”

Hervé has lead the MaaT Pharma project since its inception phase in December 2014. Hervé worked previously as an entrepreneur in residence for venture capital firms related to their investments in the Healthcare field. In parallel, he also worked as a consultant for biotechnology companies where he led transformation programs. He was previously an executive director, leading a multidisciplinary team, at Biomnis, a specialist in medical testing. Combined with his previous experience at Bio-Rad, a top-10 medical diagnostics Company, , he brings to MaaT Pharma a strong track record in operational leadership in the Life Sciences field and a capacity to translate medical notions into a strategic business plan. Hervé was awarded Entrepreneur of the Year in Healthcare (2016), recognition of his outstanding contribution to the development of MaaT Pharma.

Dr Pierre Belichard

Dr Pierre Belichard

Non executive Chairman of the Board

PharmD, PhD, MBA from INSEAD

Pierre Belichard is also founder and CEO of Enterome Bioscience. VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and was instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi through acquisition 2009 for €370m, less than five years after inception. Previously, Pierre has held various roles in Business Development and Commercial operations at UroGene Ethypharm and Fournier Pharma.

Dr Joël Doré

Dr Joël Doré

Scientific Advisor

PhD in Intestinal Microbiology

Main publications :   

Joël is a research Director at INRA and Scientific Director of MetaGenoPolis (mgps.eu), a Unit of the Micalis Institute “Food and Gut Microbiology for Human Health”. He joined INRA in 1983 and received his PhD from the University of Illinois at Urbana-Champaign, USA, in 1988. He trained as gut microbial ecologist and developed expertise in intestinal metagenomics towards diagnostic and prognostic applications as well as food-microbe-host interactions. Joël aims to contribute to a better understanding of the intestinal ecosystem in order to support therapeutic choices in the medical area, as well as science-based recommendations in health nutrition. Joël Doré chairs the gutmicrobiotaforhealth.com scientific web-platform. He was also a member of the working group constituted by the ANSM (French Regulatory Agency) for standardization of FMT in clinical pratice and was recently awarded the Marcel Dassault prize for his research on mental illness.

Pr Mohamad Mohty

Pr Mohamad Mohty

Medical haematology-oncology Advisor

MD, PhD

Main publications :   

Mohamad Mohty is Professor of Hematology and Head of the Hematology Department at Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France). He obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. He is also Head of a translational research team (INSERM U938, team N°7) at the Saint-Antoine Research centre in Paris. He is currently president of the European Society for Blood and Marrow Transplantation (EBMT) and has been instrumental in introducing FMT to this professional association. He is a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation (ASBMT), and European Hematology Association (EHA).

Dr Pierre Rimbaud

Dr Pierre Rimbaud

Medical Advisor

MD

Pierre is the co-founder of a number of companies, other than MaaT Pharma, that are involved in the field of nutrition and gut microbiome (Enterome Bioscience, Indigo Therapeutics, Targedys). After practicing and teaching medicine for a  number of years, he set a consulting practise specialized in pharmaceutical development and healthcare marketing, and became a regular advisor for Seventure Partners and Health for Life Capital.

Board Of Directors

Isabelle de Crémoux

Isabelle de Crémoux

Director

Isabelle de Cremoux is the Chairman and CEO of Seventure Partners and manages the Life Sciences team. Seventure Partners is a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, industrial biotechnologies/cleantech and nutrition. The specific ‘core’ of Seventure’s investment strategy is ‘nutrition, health and wellness’, with a particular focus on the intestinal microbiome. Graduating as an engineer from Ecole Centrale in Paris, Isabelle started her career at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions over 6 years in the field of management accounting, clinical research then Business Development. She then became Associate Director of Business Development at Fournier/Abbott signing a number of deals in Europe and in the US. Isabelle joined Seventure in July 2001 to create the life sciences department. As leader of the life sciences team and manages direct investments, mainly in France and Scandinavia with a focus on biotech, nutrition, personalized medicine and especially in the microbiome area. Isabelle’s track record includes Santaris (sold to Roche for $450 million in August 2014), Argenx (listed), OPI pharma (sold to Eusa for € 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

Eric de la Fortelle

Eric de la Fortelle

Director

Dr. Eric de La Fortelle is a Venture Partner in the Life Sciences Team of Seventure Partners, a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, industrial biotechnologies/cleantech and nutrition. The specific ‘core’ of Seventure’s investment strategy is ‘nutrition, health and wellness’, with a particular focus on the intestinal microbiome. Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations). Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and Physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA (honors) from INSEAD.

Karine Lignel

Karine Lignel

Director

Engineer

Karine LIGNEL is an Engineer (Food Science, ENSIA and holds an MBA in Finance and Accounting (IGIA -ESSEC). She spent seven years in the food industry, mainly in technical positions and joined venture capital in 2000, investing mainly in the life sciences area. Since 2000, she has been appointed to more than 20 board memberships. CM-CIC Innovation is a subsidiary of CM-CIC Investissement, the Crédit Mutuel – CIC Group’s investment and merchant bank division. With more than € 2.6 billion worth of equity under management and over 600 portfolio companies, CM-CIC Investissement is a key player in capital investment in France, backed by its own equity resources.

CM-CIC Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, information technology, industrial innovations or the environment.

Karine is the CEO of the Venture Capital team at CM-CIC Innovation, which has an active portfolio of 35 companies. Her field of expertise is fast-growing technological companies. She has chosen and invested in more than 15 companies and helped manage more than 40 companies, working with them on their strategic plans. She has been heavily involved in multiple refinancing rounds and has been key in three industrial exits as well as two successful IPOs.

Jean-Marie Lefevre

Jean-Marie Lefevre

Director

Engineer, MBA

Jean-Marie Lefevre is CEO of Biocodex, an independent multinational pharmaceutical company specialized in gastroenterology, pain management, neuropsychiatry, otolaryngology, rheumatology and pediatrics. Jean-Marie Lefevre has a long-track record as CEO.
Starting out as a Strategic Consultant at the Boston Consulting Group in Paris and Chicago, he cofounded Spizza 30, before joining the Bongrain group, where he was appointed CEO of the Scandinavian Fish Co and Nutrimer. In 1994, he joined LVMH and specifically PommeryChampagne, where he became CEO. In 2000, he left the Group to develop some entrepreneurial projects. He worked briefly at Aoste Group before moving to Biocodex which, under his leadership, is booming having grown its workforce from 250 to 960 employees.
.

Julien Samson

Julien Samson

Independent Director

Julien Samson was appointed Vice-President – Commercial Operations Pharmaceuticals for GlaxoSmithKline France in October 2012. He has been a member of the Respiratory Franchise Board of GSK at a global level since March 2015. He was Deputy General Director of the Academic Medical Center of Lyon (2009-2012), social welfare technical advisor to Mr. Nicolas Sarkozy, President of French (2007-2009), to Mr. Thierry Breton, Economy, Finance & Industry Minister, and to Mr. Jean-François Copé, Budget and State Reform Minister & Government Spokesman (2005-2007), and was responsible for Healthcare and Solidarity policies for the Budget Directorate of the Finance Ministry. Julien was vice-president of the Scientific Council for the National Agency to boost Hospital Performance (2009-2013). Graduate of the Institute of Political Studies of Paris (1998), he is an alumni of the National School of Administration (2002). He has published four books: Managing hospital (2012), Political economy of the organic law on Budget Acts (2007), Propositions for reform of the fiscal governance (2005) and The police headquarters in the service of the Parisians (2000).

Stéphanie Mercier-Arrabal

Stéphanie Mercier-Arrabal

Censor

Stephanie Mercier-Arrabal has a PhD in Microbiology with a Master’s degree in Management of innovation (Neoma Business school). She has 12 years of experience in business development. Since 2011, she is the deputy director of the Carnot institute Qualiment, a network of academic laboratories which offers its private partners a large range of research skills in the fields of human nutrition and health. At INRA Transfert, the INRA subsidiary in charge of technology transfer, she is the head of the human food and microbiology department. Her responsibilities encompass: setting up and management of R&D projects, licensing of INRA innovations, business intelligence and partnerships with industry in the economic sectors of human health and food.

Hervé Affagard

Hervé Affagard

Director

Engineer, Executive MBA, Certificate “Exploring your Microbiome”

Hervé has lead the MaaT Pharma project since its inception phase in December 2014. Hervé worked previously as an entrepreneur in residence for venture capital firms related to their investments in the Healthcare field. In parallel, he also worked as a consultant for biotechnology companies where he led transformation programs. He was previously an executive director, leading a multidisciplinary team, at Biomnis, a specialist in medical testing. Combined with his previous experience at Bio-Rad, a top-10 medical diagnostics Company, , he brings to MaaT Pharma a strong track record in operational leadership in the Life Sciences field and a capacity to translate medical notions into a strategic business plan. Hervé was awarded Entrepreneur of the Year in Healthcare (2016), recognition of his outstanding contribution to the development of MaaT Pharma.

Dr Pierre Belichard

Dr Pierre Belichard

Non executive Chairman of the Board

PharmD, PhD, MBA from INSEAD

Pierre Belichard is also founder and CEO of Enterome Bioscience. VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and was instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi through acquisition 2009 for €370m, less than five years after inception. Previously, Pierre has held various roles in Business Development and Commercial operations at UroGene, Ethypharm and Fournier Pharma.

Our Partnerships

We have partnered with INRA, since the Company’s inception to provide a complete standardized procedure from stool collection to patient administration for preparing frozen, live and ready-to-use inocula that meet good manufacturing practice as required use in the pharmaceutical industry.

   

MaaT Pharma and Biocodex joined forces to industrialize Fecal Microbiota Transfer.
This agreement has two main components, one is to establish the long-term blueprint of our industrial platform and the other one, to develop an oral form of our product.

MaaT Pharma is a partner of the collaborative LUMIERE project aimed at developing therapies to overcome primary resistance of anti-cancer treatments using the power of the Microbiome.
This project is coordinated by the Institute “Gustave Roussy” and includes key academics leading the Microbiome research such as INRA, INSERM, Méditerranée Infection Foundation, Institut Pasteur, Unicancer, Université Paris-Sud, Universite Paris-Descartes as well as leading Pharma corporations such as AstraZeneca, and Sanofi.

MaaT Pharma and Bioaster started a collaboration aimed at developing the next generation of our products with a proprietary process of fecal microbiota expansion.

The implementation of our GMP platform dedicated to FMT, the 1st in Europe, was achieved in 2016 in collaboration with Accinov. Our new formulation MaaT013 is also produced under this agreement and will allow MaaT Pharma to supply the whole of Europe with our microbiota-based experimental drugs.

MaaT Pharma has started a collaboration with EMI-Wissler to develop and industrialize the collection device which guaranties the standardization and safety of the starting material collection.

MaaT Pharma and UCA have been working together on the development of a new model for dysbiosis in vitro assessment.

OUR ECOSYSTEM

Since our creation in December 2014, Seventure, a subsidiary of Natixis, with it’s the first European fund devoted to Microbiome investments “Health for Life”, has been a shareholder along with CM-CIC Innovation, one of the leading financers in high tech companies in France, Biocodex, an independent multinational pharmaceutical leader focused initially on probiotics, and finally the National Institute for Agricultural Research (INRA,) one of the leading academic centers in the field of Microbiota. As of March 2018, MaaT Pharma has raised 12 m€ in equity and 5+ m€ in non-dilutive funding thanks to the support from Bpifrance and our banking pool CIC and BNP Paribas

We are located into the Gerland Biodistrict, in Lyon, a vibrant ecosystem composed of leading businesses, SMEs and start-ups, research laboratories, universities and elite institutions, where we have established successful partnerships, notably to set the first CMC capability to perform Fecal Microbiota Transfer in Europe as early as 2016. We are also a member of the Lyonbiopole Cluster, the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.

MaaT Pharma has established several strong business partnerships. In our mainstream we developed a very efficient academic-industrial translational collaboration with two entities from INRA (Institut National de la Recherche Agronomique aka French National Institute for Agricultural Research): Micalis and MetaGenoPolis to design our proprietary Fecal Microbiota Transfer process which is the engine of our drug developments platform. We also developed an industrial partnership with Biocodex in the domain of the development of an oral form. These two collaborations have led to the filing of 5 patent families. We also have collaboration in other areas to support our innovations

MaaT Pharma targets to develop product that would be primarily prescribed by physicians in hospitals. We have, to date, completed already several clinical trials which took place in 12 different hospitals in France where we assess, initially, our drug candidates. We are now expanding geographically to 15 additional hospitals in Europe thanks to our clinical trial in acute GvHD.

The Microbiome industry is an emerging industry, especially the notion of developing therapeutics sourced from Gut Microbiota. As of today three main approaches are pursued: Fecal microbiotherapy (via enteral or oral route), Microbiota modulators (agonists or antagonists) or Molecules mimicking microbial components or products. We compete in the field of developing drugs based on the concept of Fecal microbiotherapy, an approach which has showed the highest efficacy into the therapeutic area of Clostridium difficile.

We are working in coordination with the French regulatory agency (ANSM), since we designed, in 2014, our initial clinical development program framework aiming at evaluating our microbiota-based drugs. Since then, we have extended our discussions at the EMA level as well as local competent national authorities and the FDA, in the USA. As for our medical devices, they were developed in line with the 93/42/CEE directive. We are aiming at obtaining a CE marking for all our devices. To date, our collection device is CE marked, whereas the certification for our class II storage bag and accessories is expected by Q2 -2018.

Financing


Since our creation in December 2014, Seventure, a subsidiary of Natixis, with it’s the first European fund devoted to Microbiome investments “Health for Life”, has been a shareholder along with CM-CIC Innovation, one of the leading financers in high tech companies in France, Biocodex, an independent multinational pharmaceutical leader focused initially on probiotics, and finally the National Institute for Agricultural Research (INRA,) one of the leading academic centers in the field of Microbiota. As of March 2018, MaaT Pharma has raised 12 m€ in equity and 5+ m€ in non-dilutive funding thanks to the support from Bpifrance and our banking pool CIC and BNP Paribas .

Regulatory Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Regulatory Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

Industry Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Industry Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

Main Partnerships Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Main Partnerships Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

CLUSTERS Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

Financing Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Financing Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

Partnership Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Partnership Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

Financing


Ulluptae ctumqui suntis cora conem ipsae sedi quamet doluptatus.

Aquatis simaximagnis reici aut audant facea sitint omnihillique quatiori blaut officae in peditis simporum et aut quo bla duciend aepeditiam esto dolles undam quidem fugiand itiur, ut debit quunt la dolorum exeriae. Hent autat evelit faccate eum fuga. Poratatur

440px-Maat.svg

 

MaaT is originally the name of the goddess of balance, truth and order in Ancient Egypt. These notions ruled over the entire Egyptian society.

This mythological reference illustrates on the one hand at the level of human individuals the phenomenon of microbiota-host symbiosis (balance) and, on the other hand at the broader level of humanity, our team’s intention to embrace a societal project designed to deeply change our contemporary medical field.

MaaT also stands for Microbiota as a Therapy implying a very innovative way of curing people and preventing